Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-29
2005-03-29
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S239000, C544S242000, C514S272000
Reexamination Certificate
active
06872726
ABSTRACT:
Disclosed are compounds of formula (I):wherein R1, R2, W and X of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 5602181 (1997-02-01), Grammenos et al.
patent: 6080763 (2000-06-01), Regan et al.
patent: 6262112 (2001-07-01), Mittendorf et al.
patent: 6287381 (2001-09-01), Klocek
patent: 6297381 (2001-10-01), Cirillo et al.
patent: 6319721 (2001-11-01), Kosaka
patent: 6329415 (2001-12-01), Cirillo et al.
patent: 6358945 (2002-03-01), Breitfelder et al.
patent: 6492393 (2002-12-01), Breitfelder et al.
patent: 20020065296 (2002-05-01), Dumas et al.
patent: 20030008868 (2003-01-01), Cirillo et al.
patent: 20030083333 (2003-05-01), Cirillo et al.
patent: 20030105091 (2003-06-01), Riedl et al.
patent: 20030139605 (2003-07-01), Riedl et al.
patent: WO9932110 (1999-07-01), None
patent: WO 9932463 (1999-07-01), None
patent: WO 0041698 (2000-07-01), None
patent: WO 0136403 (2001-05-01), None
patent: WO 02083628 (2002-10-01), None
patent: WO 02092576 (2002-11-01), None
Chodorowska, Grazyna; Plasma concentrations if IFN-y and TNF-a in psoriatic patients before and after local treatment with dithranol ointment. Journal of European Academy of Dermatology and Venersology: 10 (1996) 147-151.
Higham, M.A., et al; Tumour necrosis factor-a gene promoter polymorphism in chronic obstructive pulmonary disease. Euro Respir. J 2000: 15: 281-284.
Takabatake, N., et al; The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor-a System in Patients with Chronic Obstructive Pulmonary Disease ; American Journal of Respiratory and Critical Care Medicine: vol. 161 1179-1184.
Tumor Necrosis Factor Inhibitors—Rx Intelligence—Early Alert Report—Executive Summary.
Cirillo Pier Francesco
Hammach Abdelhakim
Kamhi Victor
Moss Neil
Pargellis Christopher
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino A. P.
Devlin M. E.
Morris M. P.
Shameem Golam M M
LandOfFree
Fluorinated di-aryl urea compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorinated di-aryl urea compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorinated di-aryl urea compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3433766